1. Home
  2. SON vs MIRM Comparison

SON vs MIRM Comparison

Compare SON & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sonoco Products Company

SON

Sonoco Products Company

HOLD

Current Price

$42.88

Market Cap

4.0B

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$63.86

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SON
MIRM
Founded
1899
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
3.4B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SON
MIRM
Price
$42.88
$63.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
11
Target Price
$56.83
$87.55
AVG Volume (30 Days)
878.5K
560.0K
Earning Date
10-22-2025
11-04-2025
Dividend Yield
4.99%
N/A
EPS Growth
116.52
N/A
EPS
6.30
N/A
Revenue
$7,114,053,000.00
$471,794,000.00
Revenue This Year
$45.04
$53.78
Revenue Next Year
N/A
$19.91
P/E Ratio
$6.74
N/A
Revenue Growth
67.86
53.66
52 Week Low
$38.65
$36.88
52 Week High
$52.77
$78.55

Technical Indicators

Market Signals
Indicator
SON
MIRM
Relative Strength Index (RSI) 62.04 34.17
Support Level $40.39 $63.66
Resistance Level $41.76 $66.77
Average True Range (ATR) 0.85 2.93
MACD 0.18 -0.69
Stochastic Oscillator 96.71 6.51

Price Performance

Historical Comparison
SON
MIRM

About SON Sonoco Products Company

Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: